CR10173A - Método para la utilización de células progenitoras hepáticas en el tratamiento de la disfunción hepática - Google Patents

Método para la utilización de células progenitoras hepáticas en el tratamiento de la disfunción hepática

Info

Publication number
CR10173A
CR10173A CR10173A CR10173A CR10173A CR 10173 A CR10173 A CR 10173A CR 10173 A CR10173 A CR 10173A CR 10173 A CR10173 A CR 10173A CR 10173 A CR10173 A CR 10173A
Authority
CR
Costa Rica
Prior art keywords
hepatic
cells
progeniting
treatment
dysfunction
Prior art date
Application number
CR10173A
Other languages
English (en)
Inventor
Johnston Mark
Ludlow John
Sherwood Sonya
Original Assignee
Biodiesel De Andalucía 2004 S A E
Meern Bv Engelhard De
Vesta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biodiesel De Andalucía 2004 S A E, Meern Bv Engelhard De, Vesta Therapeutics Inc filed Critical Biodiesel De Andalucía 2004 S A E
Publication of CR10173A publication Critical patent/CR10173A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/407—Liver; Hepatocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/067—Hepatocytes
    • C12N5/0672—Stem cells; Progenitor cells; Precursor cells; Oval cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Es una incorporación de la presente invención, se provee un método para repoblar el compartimiento del hígado de un mamifero el cual incluye proveer células progenitoras hepáticas aisladas y administrar dichas células progenitoras hepáticas aisladas dentro del compartimiento del hígado del mamifero; en donde la administración es llevada a cabo con concentraciones bajas de inmunosupresores.
CR10173A 2005-12-22 2008-07-22 Método para la utilización de células progenitoras hepáticas en el tratamiento de la disfunción hepática CR10173A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75259705P 2005-12-22 2005-12-22

Publications (1)

Publication Number Publication Date
CR10173A true CR10173A (es) 2008-11-11

Family

ID=38218575

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10173A CR10173A (es) 2005-12-22 2008-07-22 Método para la utilización de células progenitoras hepáticas en el tratamiento de la disfunción hepática

Country Status (12)

Country Link
US (1) US20070148141A1 (es)
EP (1) EP1976982A4 (es)
JP (1) JP2009521459A (es)
KR (1) KR20080091776A (es)
AU (1) AU2006331706A1 (es)
BR (1) BRPI0620636A2 (es)
CA (1) CA2634909A1 (es)
CR (1) CR10173A (es)
IL (1) IL192378A0 (es)
RU (1) RU2008130098A (es)
TW (1) TW200800241A (es)
WO (1) WO2007075812A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2368384C2 (ru) * 2007-08-24 2009-09-27 Федеральное государственное учреждение "Научный Центр акушерства, гинекологии и перинатологии Федерального агентства по высокотехнологичной медицинской помощи" Биотрансплантат, способ лечения хронических заболеваний печени и способ лечения цирроза печени и портальной гипертензии
JPWO2011102532A1 (ja) * 2010-02-16 2013-06-17 国立大学法人九州大学 誘導肝細胞
EP2758780A4 (en) * 2011-09-22 2015-09-16 Marv Entpr Llc METHOD OF TREATING MULTIPLE SCLEROSIS
JP5950235B2 (ja) 2011-09-30 2016-07-13 公立大学法人横浜市立大学 肝細胞の分化誘導方法、ヒト化肝臓キメラ非ヒト動物の作製方法
RU2018128598A (ru) * 2016-01-08 2020-02-11 Кинити Ко., Лтд. Способ продуцирования стволовых клеток/клеток-предшественников печени из зрелых клеток печени с использованием низкомолекулярного соединения

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6069005A (en) * 1991-08-07 2000-05-30 Albert Einstein College Of Medicine Of Yeshwa University Hapatoblasts and method of isolating same
AU779706B2 (en) * 1999-01-19 2005-02-10 University Of North Carolina At Chapel Hill, The Human liver progenitors
US7456017B2 (en) 1999-10-01 2008-11-25 University Of North Carolina At Chapel Hill Processes for clonal growth of hepatic progenitor cells
CA2392615A1 (en) * 1999-12-06 2001-06-07 The General Hospital Corporation Pancreatic stem cells and their use in transplantation
HUE032238T2 (en) * 2002-03-15 2017-09-28 Univ North Carolina Chapel Hill Primitive and proximal liver stem cells
SG155053A1 (en) * 2002-07-19 2009-09-30 Vesta Therapeutics Inc Method of obtaining viable human liver cells, including hepatic stem/progenitor cells

Also Published As

Publication number Publication date
US20070148141A1 (en) 2007-06-28
BRPI0620636A2 (pt) 2011-11-16
JP2009521459A (ja) 2009-06-04
EP1976982A2 (en) 2008-10-08
TW200800241A (en) 2008-01-01
WO2007075812A3 (en) 2008-01-17
KR20080091776A (ko) 2008-10-14
IL192378A0 (en) 2008-12-29
RU2008130098A (ru) 2010-01-27
AU2006331706A1 (en) 2007-07-05
EP1976982A4 (en) 2009-09-16
CA2634909A1 (en) 2007-07-05
WO2007075812A2 (en) 2007-07-05

Similar Documents

Publication Publication Date Title
MX2009010683A (es) Conjugado de wortmanina-rapamicina y usos del mismo.
AR059089A1 (es) Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
MX355708B (es) Compuestos de d-aminoacidos para enfermedades del higado.
WO2007095594A3 (en) Methods and compositions for enhancing engraftment of hematopoietic stem cells
CL2008001745A1 (es) Compuestos derivados de imidazo[1,2-a]pirazina; composición farmacéutica; y uso de los compuestos como inhibidores de la proteína quinasa en el tratamiento del cáncer.
MX2018002723A (es) Macrociclicos peptidomimeticos y usos de los mismos.
CL2012000248A1 (es) Compuesto conjugado de insulina; procedimiento de preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; kit farmaceutico; uso en el tratamiento de trastornos mediados por insulina.
CL2009000200A1 (es) Compuestos derivados de 2,7-naftiridinas-1-ona, mediadores de syk; composicion farmaceutica; y uso en el tratamiento de una enfermedad inflamatoria, respiratoria, proliferativa celular o autoinmune.
MX2014008773A (es) Composiciones y metodos para el uso de ésteres de forbol.
CR9881A (es) Polimorfos de la sal benzoato de 2-[[6-[(3r)-3amino-1-piperidinil]-3,4-dihidro-3-metil-2,4-dioxo-1(2h)-pirimidinil]metil]-benzonitrilo y metodos de uso para los mismos
WO2007001662A3 (en) Instant messaging with search
CL2009000393A1 (es) Composición farmaceutica que comprende a) un agente farmaceutico activable, b) un agente activo plasmonico; util para el tratamiento de trastornos de proliferación celular.
ATE494039T1 (de) Gerät für die renale neuromodulation
AR073563A1 (es) Terapia de combinacion para el tratamiento de diabetes y estados relacionados
ECSP088324A (es) 2-amino-7,8-dihidro-6h-pirido[4,3-d]pirimidina-5-onas
CL2012000707A1 (es) Compuestos derivados de [5-(pirrolo[1,2-c][1.2.3]triazin-7-il)tetrahidrofuran-2-il]metanol; composición farmacéutica; y su uso para el tratamiento de la hepatitis c.
AR060306A1 (es) Terapia de combinacion de anticuerpos contra ctla4
CL2008001373A1 (es) Compuestos derivados de fenilamino-benceno sustituidos; metodo de preparacion; composicion farmaceutica; kit farmceuticos; y uso de dichos compuestos en el tratamiento del cancer.
CR10173A (es) Método para la utilización de células progenitoras hepáticas en el tratamiento de la disfunción hepática
ES2526548T3 (es) Uso de CD83 en terapias de combinación
CL2011000116A1 (es) Compuestos derivados de imidazo[1,2-a]piridina; procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios; y uso en el tratamiento del cancer.
MX2014014662A (es) Manufactura de degarelix.
DOP2009000208A (es) Métodos de tratamiento del cáncer mediante administración de combinaciones de il-18 humana
HN2006009000A (es) Formas farmaceuticas con propiedades farmacocineticas mejoradas
SV2008002856A (es) 2-amino-7, 8-dihidro-6h-pirido [4,3-d] pirimidina-5-onas

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)